The Readout Loud

As long as there's been a medical system, it's been one that is rife with instances of mistreatment — both on the individual and community levels — that have harmful effects on how Black Americans view the health care system. In the first episode of the new STAT podcast Color Code, host Nick St. Fleur speaks with doctors, researchers, and a patient who are all trying to repair the relationship between Black people and the medical institution.

You can find Color Code on any platform you use to get your podcasts. Episodes are released every other week.

Are Covid-19 vaccines a sustainable business? Was Aduhelm an aberration? And what comes after Omicron?

Senior writer Helen Branswell joins us to discuss the latest twists in the pandemic, including rising case counts, next-generation vaccines, and the latest data from pediatric trials. We also dive into the latest news in the life sciences, including Moderna's grand ambitions, Al Sandrock's new job, and the next big FDA debate.

How should pharma treat Russia? Why can't Congress pass a drug pricing bill? And what does wastewater portend for the pandemic?

First, we discuss the drug industry's response to Russia's invasion of Ukraine, and STAT reporter Isabella Cueto joins us to explain how the war has affected the quietly vibrant Ukrainian biotech industry. Then, STAT Washington correspondent Nicholas Florko calls in to review Congress' years of failure to pass laws on drug pricing and examine whether bipartisan support can ever result in actual legislation. We also run through the latest news in the life sciences, including Ashish Jha's new job, global Covid-19 surges, and a long-delayed manuscript from Biogen.

Can biotech companies age gracefully? Where did Covid-19 come from? And does Theranos make for good television?

We cover all that and more this week. We examine Gilead Sciences' recent struggles and what the company's predicament says about the drug industry. Then, MIT Technology Review reporter Antonio Regalado joins us to discuss his new podcast investigating the origins of Covid-19. We also discuss the latest Theranos trial, playing Elizabeth Holmes on TV, and how we managed to make 200 episodes of this show.

Is "test to treat" too good to be true? Does it really matter who gets credit for CRISPR? And what's the offramp for Covid-19?

We cover all that and more this week. Physician and researcher Kavita Patel joins us to explain why President Biden's plans for Covid-19 — including an ambitious idea to distribute antiviral treatments — might not be so simple. We also discuss some milestone data in the quest to turn CRISPR into medicine and the latest twist in the quest to figure out who invented it.

How many Covid-19 vaccines does the world really need? What will it take to address inequality in American health care? And should people be nicer to Moderna?

First, we discuss the latest news in Covid-19 vaccines, including data from Sanofi and GlaxoSmithKline, the future of Novavax, and what comes next for Moderna. Then, STAT’s Usha Lee McFarling joins us to talk about a groundbreaking investigation into racial and ethnic disparities in American medicine — and why almost nothing has changed in the 20 years since it was published.

Will there be a new ALS drug this year? What business does Wall Street have with CRISPR? And when can kids get Covid-19 vaccines?

We cover all that and more this week. First, STAT's Nicholas Florko joins us to preview the trials ahead for Robert Califf as he retakes the reins at the FDA — including a high-profile decision on a new treatment for ALS. Then, CRISPR pioneer Jennifer Doudna and financier Marty Chavez join us to talk about the future of genome editing and the investments they plan to make in it. We also discuss the latest on Eric Lander, the Covid-19 vaccine meeting that wasn't, and the future of Chinese-developed cancer drugs.

Does Big Science have a bullying problem? Why did the FDA change its tune on China? And what's cooler than $100 billion?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss the scandalous end of Eric Lander's tenure as presidential science adviser with STAT Washington correspondent Lev Facher and science writer Megan Molteni. Then we dive into the FDA's about-face on cancer drugs developed in China and what it means for the cost of medicine in the U.S. We also explain how Pfizer's record-setting year somehow disappointed Wall Street and explore whether it's a good idea to end mask mandates.

Does President Biden care about the FDA? What can aerobics instructors teach us about genetics? And when can kids get Covid-19 vaccines?

STAT Washington correspondent Nicholas Florko joins us to chat about why Robert Califf, once a shoo-in to be the next FDA commissioner, is suddenly in serious jeopardy. Then, we examine one of the coolest drug-discovery stories in medicine with Merck’s head of research, Dean Li, who joins us to talk about the company’s efforts to develop an oral cholesterol pill targeting PCSK9.

Who gets to be an "expert" on Covid-19? Are Americans entitled to drugs that don't work? And how does the FDA deal with states' rights?

First, we discuss the FDA's decision to halt the use of two Covid-19 antibodies that don't work against Omicron — and the surprising backlash that ensued. Then, acting FDA commissioner Janet Woodcock joins us to dig into the agency's move and discuss the steps for regulation of Covid drugs. We also go over the latest news in the life sciences, including some bad news for Gilead Sciences and a rare victory for a small biotech company.